60 related articles for article (PubMed ID: 16488201)
1. Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome.
Tartaglia M; Cordeddu V; Chang H; Shaw A; Kalidas K; Crosby A; Patton MA; Sorcini M; van der Burgt I; Jeffery S; Gelb BD
Am J Hum Genet; 2004 Sep; 75(3):492-7. PubMed ID: 15248152
[TBL] [Abstract][Full Text] [Related]
2. A Novel
Kumar P; Paramasivam G; Devasia T; Prabhu M; Rai MK; Prakashini K; Mallya S; Reghunathan D; Megha A; Nayak K; Moka R
Indian J Clin Biochem; 2024 Jan; 39(1):142-145. PubMed ID: 38223010
[TBL] [Abstract][Full Text] [Related]
3. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?
Edouard T; Montagner A; Dance M; Conte F; Yart A; Parfait B; Tauber M; Salles JP; Raynal P
Cell Mol Life Sci; 2007 Jul; 64(13):1585-90. PubMed ID: 17453145
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome.
Meier AB; Raj Murthi S; Rawat H; Toepfer CN; Santamaria G; Schmid M; Mastantuono E; Schwarzmayr T; Berutti R; Cleuziou J; Ewert P; Görlach A; Klingel K; Laugwitz KL; Seidman CE; Seidman JG; Moretti A; Wolf CM
iScience; 2022 Jan; 25(1):103596. PubMed ID: 34988410
[TBL] [Abstract][Full Text] [Related]
5. Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.
Liu X; Qu CK
J Signal Transduct; 2011; 2011():195239. PubMed ID: 21799948
[TBL] [Abstract][Full Text] [Related]
6. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
8. LEOPARD Syndrome: Clinical Features and Gene Mutations.
Martínez-Quintana E; Rodríguez-González F
Mol Syndromol; 2012 Oct; 3(4):145-57. PubMed ID: 23239957
[TBL] [Abstract][Full Text] [Related]
9. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations.
Lepri F; De Luca A; Stella L; Rossi C; Baldassarre G; Pantaleoni F; Cordeddu V; Williams BJ; Dentici ML; Caputo V; Venanzi S; Bonaguro M; Kavamura I; Faienza MF; Pilotta A; Stanzial F; Faravelli F; Gabrielli O; Marino B; Neri G; Silengo MC; Ferrero GB; Torrrente I; Selicorni A; Mazzanti L; Digilio MC; Zampino G; Dallapiccola B; Gelb BD; Tartaglia M
Hum Mutat; 2011 Jul; 32(7):760-72. PubMed ID: 21387466
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI
J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643
[TBL] [Abstract][Full Text] [Related]
11. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
[TBL] [Abstract][Full Text] [Related]
12. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Ogata T; Yoshida R
Pediatr Endocrinol Rev; 2005 Jun; 2(4):669-74. PubMed ID: 16208280
[TBL] [Abstract][Full Text] [Related]
13. [PTPN11 gene mutation in LEOPARD syndrome].
Paradisi M; Pedicelli C; Ciasulli A; Pinto F; Conti E; Sarkozy A; Angelo C
Minerva Pediatr; 2005 Aug; 57(4):189-93. PubMed ID: 16172598
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Sznajer Y; Keren B; Baumann C; Pereira S; Alberti C; Elion J; Cavé H; Verloes A
Pediatrics; 2007 Jun; 119(6):e1325-31. PubMed ID: 17515436
[TBL] [Abstract][Full Text] [Related]
15. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression.
Keren A; Syrris P; McKenna WJ
Nat Clin Pract Cardiovasc Med; 2008 Mar; 5(3):158-68. PubMed ID: 18227814
[TBL] [Abstract][Full Text] [Related]
16. Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy.
Limongelli G; Hawkes L; Calabro R; McKenna WJ; Syrris P
Eur J Med Genet; 2006; 49(5):426-30. PubMed ID: 16488201
[TBL] [Abstract][Full Text] [Related]
17. Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations.
Digilio MC; Pacileo G; Sarkozy A; Limongelli G; Conti E; Cerrato F; Marino B; Pizzuti A; Calabrò R; Dallapiccola B
Birth Defects Res A Clin Mol Teratol; 2004 Feb; 70(2):95-8. PubMed ID: 14991917
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
